<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="pt" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq Bras Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12101576</article-id><article-id pub-id-type="other">00203</article-id><article-id pub-id-type="doi">10.36660/abc.20250178</article-id><article-categories><subj-group subj-group-type="heading"><subject>Minieditorial</subject></subj-group></article-categories><title-group><article-title>Detec&#x000e7;&#x000e3;o de Hipercolesterolemia Familiar em Adolescentes: o Rastreamento Universal &#x000e9; Fundamental</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1051-9434</contrib-id><name><surname>Cesena</surname><given-names>Fernando Yue</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c1" ref-type="corresp"/></contrib><aff id="aff1">
<label>1</label>
<institution content-type="orgname">Instituto Dante Pazzanese de Cardiologia</institution>
<addr-line>
<named-content content-type="city">S&#x000e3;o Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Instituto Dante Pazzanese de Cardiologia, S&#x000e3;o Paulo, SP - Brasil</institution>
</aff></contrib-group><author-notes><corresp id="c1">
<label>Correspond&#x000ea;ncia:</label>
<bold>Fernando Yue Cesena</bold>
&#x02022; Instituto Dante Pazzanese de Cardiologia - Se&#x000e7;&#x000e3;o de Hipertens&#x000e3;o e Tabagismo - Av. Dr. Dante Pazzanese, 500. CEP
<postal-code>04012-909</postal-code>
, S&#x000e3;o Paulo, SP - Brasil E-mail:
<email>cesenaf@gmail.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>122</volume><issue>3</issue><elocation-id>e20250178</elocation-id><history><date date-type="received"><day>10</day><month>3</month><year>2024</year></date><date date-type="rev-recd"><day>26</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>3</month><year>2025</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p></license></permissions><kwd-group><title>Palavras-chave</title><kwd>Hipercolesterolemia</kwd><kwd>Adolescente</kwd><kwd>Programas de Rastreamento</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="15"/></counts></article-meta></front><body><p>Hipercolesterolemia familiar (HF) &#x000e9; um dist&#x000fa;rbio gen&#x000e9;tico caracterizado pela depura&#x000e7;&#x000e3;o prejudicada de part&#x000ed;culas de lipoprote&#x000ed;na de baixa densidade (LDL) do plasma para os hepat&#x000f3;citos, resultando em n&#x000ed;veis elevados de colesterol LDL (LDL-C) no plasma e um risco significativamente aumentado de doen&#x000e7;a cardiovascular ateroscler&#x000f3;tica (DCVA) prematura. Metan&#x000e1;lises recentes indicam uma preval&#x000ea;ncia de HF de aproximadamente 1 em 310 indiv&#x000ed;duos na popula&#x000e7;&#x000e3;o geral.<sup>
<xref rid="B1" ref-type="bibr">1</xref>
,
<xref rid="B2" ref-type="bibr">2</xref>
</sup> &#x000c9; importante ressaltar que a HF continua substancialmente subdiagnosticada, e a maioria dos indiv&#x000ed;duos afetados vive com n&#x000ed;veis de LDL-C acima das metas recomendadas.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup></p><p>A identifica&#x000e7;&#x000e3;o precoce da HF &#x000e9; cr&#x000ed;tica para prevenir eventos de DCVA. De uma perspectiva fisiopatol&#x000f3;gica, a aterosclerose se desenvolve devido &#x000e0; exposi&#x000e7;&#x000e3;o arterial cumulativa a part&#x000ed;culas LDL elevadas. Tanto a magnitude de part&#x000ed;culas LDL excessivas no plasma quanto a dura&#x000e7;&#x000e3;o da exposi&#x000e7;&#x000e3;o s&#x000e3;o relevantes para o desenvolvimento e progress&#x000e3;o da placa.<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup> Nesse sentido, a HF &#x000e9; particularmente preocupante porque os indiv&#x000ed;duos afetados t&#x000ea;m n&#x000ed;veis muito altos de LDL-C desde o nascimento/inf&#x000e2;ncia. O diagn&#x000f3;stico precoce e consequente conscientiza&#x000e7;&#x000e3;o do problema aumentam a chance de ado&#x000e7;&#x000e3;o de um estilo de vida saud&#x000e1;vel a longo prazo. A redu&#x000e7;&#x000e3;o precoce do LDL-C melhora a fun&#x000e7;&#x000e3;o endotelial, atenua a progress&#x000e3;o da aterosclerose e diminui o risco de eventos coron&#x000e1;rios.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
,
<xref rid="B5" ref-type="bibr">5</xref>
,
<xref rid="B6" ref-type="bibr">6</xref>
</sup></p><p>Nesta edi&#x000e7;&#x000e3;o dos Arquivos Brasileiros de Cardiologia, um subestudo do ERICA, um estudo transversal brasileiro conduzido em 2013&#x02013;2014, avalia anormalidades lip&#x000ed;dicas sugestivas de HF em adolescentes de 12 a 17 anos da regi&#x000e3;o metropolitana de Curitiba. Entre 2.383 adolescentes avaliados, 11 (aproximadamente 0,5% ou 1 em 217) apresentaram LDL-C &#x0003e;160 mg/dL ou colesterol n&#x000e3;o-HDL &#x0003e;190 mg/dL. O rastreamento em cascata foi aplicado a parentes de primeiro grau. Nenhum dos 7 alunos avaliados tinha diagn&#x000f3;stico de HF poss&#x000ed;vel ou prov&#x000e1;vel de acordo com a vers&#x000e3;o modificada da
<italic toggle="yes">Dutch Lipid Clinic Network</italic>
(Dutch MEDPED), enquanto 3 entre 15 parentes de primeiro grau (20%) tinham crit&#x000e9;rios para HF poss&#x000ed;vel ou prov&#x000e1;vel.<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup> O estudo tem limita&#x000e7;&#x000f5;es, incluindo a falta de um diagn&#x000f3;stico definitivo de HF por teste gen&#x000e9;tico. Ainda assim, oferece uma oportunidade para discutir aspectos relevantes do diagn&#x000f3;stico de HF na juventude.</p><p>A aus&#x000ea;ncia de adolescentes com crit&#x000e9;rios positivos para HF usando o Dutch MEDPED concorda com a recomenda&#x000e7;&#x000e3;o contra o uso desta pontua&#x000e7;&#x000e3;o para diagnosticar HF em crian&#x000e7;as e adolescentes.<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup> Esses indiv&#x000ed;duos apresentam com menos frequ&#x000ea;ncia caracter&#x000ed;sticas t&#x000ed;picas da HF, como xantoma tendinoso, em compara&#x000e7;&#x000e3;o aos adultos.<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup> Al&#x000e9;m disso, a DCVA cl&#x000ed;nica, um crit&#x000e9;rio no Dutch MEDPED, ocorre tipicamente na vida adulta em indiv&#x000ed;duos com HF heterozig&#x000f3;tica. Portanto, a HF deve ser suspeita em crian&#x000e7;as/adolescentes quando o LDL-C estiver acentuadamente elevado (&#x0003e;190 mg/dL n&#x000e3;o tratado) ou naqueles com LDL-C moderadamente elevado juntamente com hist&#x000f3;rico parental de doen&#x000e7;a arterial coron&#x000e1;ria prematura, LDL-C muito elevado ou uma muta&#x000e7;&#x000e3;o gen&#x000e9;tica identificada causando HF.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
,
<xref rid="B5" ref-type="bibr">5</xref>
</sup></p><p>Testes gen&#x000e9;ticos para variantes causadoras de HF devem ser feitos sempre que poss&#x000ed;vel.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup> A identifica&#x000e7;&#x000e3;o de uma variante patog&#x000ea;nica indica um risco cardiovascular maior, melhora a ades&#x000e3;o ao tratamento e pode levar ao rastreamento em cascata para identificar parentes afetados.<sup>
<xref rid="B9" ref-type="bibr">9</xref>
,
<xref rid="B10" ref-type="bibr">10</xref>
</sup> No Brasil, o Hipercol Brasil (
<ext-link xlink:href="https://hipercolbrasil.com.br/o-programa/" ext-link-type="uri">https://hipercolbrasil.com.br/o-programa/</ext-link>
), um programa de rastreamento gen&#x000e9;tico em cascata da HF, exemplifica uma iniciativa bem-sucedida para facilitar o diagn&#x000f3;stico gen&#x000e9;tico da HF mesmo em regi&#x000f5;es distantes de centros especializados.<sup>
<xref rid="B10" ref-type="bibr">10</xref>
,
<xref rid="B11" ref-type="bibr">11</xref>
</sup></p><p>No n&#x000ed;vel comunit&#x000e1;rio, o diagn&#x000f3;stico precoce da HF depende de uma estrat&#x000e9;gia de rastreamento eficaz, o que constitui um forte argumento a favor do rastreamento universal. Neste sentido, a Atualiza&#x000e7;&#x000e3;o da Diretriz Brasileira de HF de 2021 recomenda a realiza&#x000e7;&#x000e3;o do perfil lip&#x000ed;dico para todas as crian&#x000e7;as a partir dos 10 anos ou j&#x000e1; a partir dos 2 anos em situa&#x000e7;&#x000f5;es espec&#x000ed;ficas (por exemplo, hist&#x000f3;rico parental de doen&#x000e7;a arterial coron&#x000e1;ria prematura ou LDL-C muito alto).<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup> A chance de detectar hipercolesterolemia em adolescentes n&#x000e3;o &#x000e9; irris&#x000f3;ria. Uma publica&#x000e7;&#x000e3;o anterior do estudo ERICA mostrou que 25% das adolescentes do sexo feminino e 15% dos do sexo masculino tinham altos n&#x000ed;veis de colesterol total plasm&#x000e1;tico (&#x02265;170 mg/dL), enquanto outros 26% das mulheres e 23% dos homens tinham colesterol total entre 150 mg/dL e 169 mg/dL, resultando em uma estimativa de quase 3 milh&#x000f5;es de adolescentes brasileiros com colesterol sangu&#x000ed;neo elevado.<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup></p><p>A falta de uma estrat&#x000e9;gia estruturada para rastreamento lip&#x000ed;dico universal na pr&#x000e1;tica rotineira representa uma oportunidade perdida para redu&#x000e7;&#x000e3;o precoce do risco cardiovascular por meio de interven&#x000e7;&#x000f5;es no estilo de vida e terapias preventivas. Outras barreiras significativas permanecem, incluindo baixa conscientiza&#x000e7;&#x000e3;o sobre HF, especialmente em crian&#x000e7;as/adolescentes, percep&#x000e7;&#x000f5;es err&#x000f4;neas do paciente em rela&#x000e7;&#x000e3;o ao risco cardiovascular e baixa obten&#x000e7;&#x000e3;o da meta de LDL-C em indiv&#x000ed;duos com hipercolesterolemia grave.<sup>
<xref rid="B14" ref-type="bibr">14</xref>
,
<xref rid="B15" ref-type="bibr">15</xref>
</sup> Abordar essas quest&#x000f5;es requer uma estrat&#x000e9;gia multifacetada envolvendo ag&#x000ea;ncias governamentais de sa&#x000fa;de, sociedades m&#x000e9;dicas e grupos organizados de pacientes, com programas abrangentes e campanhas educacionais direcionadas a profissionais de sa&#x000fa;de e &#x000e0; comunidade em geral. Essas a&#x000e7;&#x000f5;es s&#x000e3;o essenciais para reduzir efetivamente o impacto da HF e o risco de DCVA associado.</p></body><back><fn-group><fn fn-type="other" id="fn1"><p><bold>Minieditorial referente ao artigo:</bold> Rastreamento em Cascata em Adolescentes com Altera&#x000e7;&#x000f5;es Lip&#x000ed;dicas Sugestivas de Hipercolesterolemia Familiar: Dados do Estudo ERICA &#x02013; Curitiba</p></fn></fn-group><ref-list><title>Refer&#x000ea;ncias</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beheshti</surname><given-names>SO</given-names></name>
<name><surname>Madsen</surname><given-names>CM</given-names></name>
<name><surname>Varbo</surname><given-names>A</given-names></name>
<name><surname>Nordestgaard</surname><given-names>BG</given-names></name>
</person-group><article-title>Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects</article-title><source>
J Am Coll Cardiol
</source><year>2020</year><volume>75</volume><issue>20</issue><fpage>2553</fpage><lpage>2566</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.03.057</pub-id><pub-id pub-id-type="pmid">32439005</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>P</given-names></name>
<name><surname>Dharmayat</surname><given-names>KI</given-names></name>
<name><surname>Stevens</surname><given-names>CAT</given-names></name>
<name><surname>Sharabiani</surname><given-names>MTA</given-names></name>
<name><surname>Jones</surname><given-names>RS</given-names></name>
<name><surname>Watts</surname><given-names>GF</given-names></name>
<etal/>
</person-group><article-title>Prevalence of Familial Hypercholesterolemia Among the General Population and Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis</article-title><source>
Circulation
</source><year>2020</year><volume>141</volume><issue>22</issue><fpage>1742</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.044795</pub-id><pub-id pub-id-type="pmid">32468833</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watts</surname><given-names>GF</given-names></name>
<name><surname>Gidding</surname><given-names>SS</given-names></name>
<name><surname>Hegele</surname><given-names>RA</given-names></name>
<name><surname>Raal</surname><given-names>FJ</given-names></name>
<name><surname>Sturm</surname><given-names>AC</given-names></name>
<name><surname>Jones</surname><given-names>LK</given-names></name>
<etal/>
</person-group><article-title>International Atherosclerosis Society Guidance for Implementing Best Practice in the Care of Familial Hypercholesterolaemia</article-title><source>
Nat Rev Cardiol
</source><year>2023</year><volume>20</volume><issue>12</issue><fpage>845</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1038/s41569-023-00892-0</pub-id><pub-id pub-id-type="pmid">37322181</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ference</surname><given-names>BA</given-names></name>
<name><surname>Braunwald</surname><given-names>E</given-names></name>
<name><surname>Catapano</surname><given-names>AL</given-names></name>
</person-group><article-title>The LDL Cumulative Exposure Hypothesis: Evidence and Practical Applications</article-title><source>
Nat Rev Cardiol
</source><year>2024</year><volume>21</volume><issue>10</issue><fpage>701</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1038/s41569-024-01039-5</pub-id><pub-id pub-id-type="pmid">38969749</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wiegman</surname><given-names>A</given-names></name>
<name><surname>Gidding</surname><given-names>SS</given-names></name>
<name><surname>Watts</surname><given-names>GF</given-names></name>
<name><surname>Chapman</surname><given-names>MJ</given-names></name>
<name><surname>Ginsberg</surname><given-names>HN</given-names></name>
<name><surname>Cuchel</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Familial Hypercholesterolaemia in Children and Adolescents: Gaining Decades of Life by Optimizing Detection and Treatment</article-title><source>
Eur Heart J
</source><year>2015</year><volume>36</volume><issue>36</issue><fpage>2425</fpage><lpage>2437</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv157</pub-id><pub-id pub-id-type="pmid">26009596</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luirink</surname><given-names>IK</given-names></name>
<name><surname>Wiegman</surname><given-names>A</given-names></name>
<name><surname>Kusters</surname><given-names>DM</given-names></name>
<name><surname>Hof</surname><given-names>MH</given-names></name>
<name><surname>Groothoff</surname><given-names>JW</given-names></name>
<name><surname>de Groot</surname><given-names>E</given-names></name>
<etal/>
</person-group><article-title>20-Year Follow-Up of Statins in Children with Familial Hypercholesterolemia</article-title><source>
N Engl J Med
</source><year>2019</year><volume>381</volume><issue>16</issue><fpage>1547</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1816454</pub-id><pub-id pub-id-type="pmid">31618540</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bento</surname><given-names>VFE</given-names></name>
<name><surname>Kaestner</surname><given-names>TLL</given-names></name>
<name><surname>Vargas</surname><given-names>A</given-names><suffix>Junior</suffix></name>
<name><surname>Lopes</surname><given-names>RB</given-names></name>
<name><surname>Scariot</surname><given-names>FP</given-names></name>
<name><surname>Hollas</surname><given-names>LL</given-names></name>
<etal/>
</person-group><article-title>Cascade Screening in Adolescents with Lipid Disorders Suggestive of Familial Hypercholesterolemia: Findings from the ERICA Study in Curitiba</article-title><source>
Arq Bras Cardiol
</source><year>2025</year><volume>122</volume><issue>3</issue><elocation-id>e20240468</elocation-id><pub-id pub-id-type="doi">10.36660/abc.20240468i</pub-id><pub-id pub-id-type="pmid">40172431</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Casula</surname><given-names>M</given-names></name>
<name><surname>Gazzotti</surname><given-names>M</given-names></name>
<name><surname>Capra</surname><given-names>ME</given-names></name>
<name><surname>Olmastroni</surname><given-names>E</given-names></name>
<name><surname>Galimberti</surname><given-names>F</given-names></name>
<name><surname>Catapano</surname><given-names>AL</given-names></name>
<etal/>
</person-group><article-title>Refinement of the Diagnostic Approach for the Identification of Children and Adolescents Affected by Familial Hypercholesterolemia: Evidence from the LIPIGEN Study</article-title><source>
Atherosclerosis
</source><year>2023</year><volume>385</volume><fpage>117231</fpage><lpage>117231</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2023.117231</pub-id><pub-id pub-id-type="pmid">37648636</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sturm</surname><given-names>AC</given-names></name>
<name><surname>Knowles</surname><given-names>JW</given-names></name>
<name><surname>Gidding</surname><given-names>SS</given-names></name>
<name><surname>Ahmad</surname><given-names>ZS</given-names></name>
<name><surname>Ahmed</surname><given-names>CD</given-names></name>
<name><surname>Ballantyne</surname><given-names>CM</given-names></name>
<etal/>
</person-group><article-title>Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel</article-title><source>
J Am Coll Cardiol
</source><year>2018</year><volume>72</volume><issue>6</issue><fpage>662</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2018.05.044</pub-id><pub-id pub-id-type="pmid">30071997</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>PRS</given-names></name>
<name><surname>Jannes</surname><given-names>CE</given-names></name>
<name><surname>Oliveira</surname><given-names>TGM</given-names></name>
<name><surname>Krieger</surname><given-names>JE</given-names></name>
<name><surname>Santos</surname><given-names>RD</given-names></name>
<name><surname>Pereira</surname><given-names>AC</given-names></name>
</person-group><article-title>Pharmacological Treatment with Lipid-Lowering Agents after Molecular Identification of Familial Hypercholesterolemia: Results from the Hipercol Brasil Cohort</article-title><source>
J Clin Lipidol
</source><year>2022</year><volume>16</volume><issue>2</issue><fpage>198</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.jacl.2022.01.005</pub-id><pub-id pub-id-type="pmid">35181259</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jannes</surname><given-names>CE</given-names></name>
<name><surname>Silvino</surname><given-names>JPP</given-names></name>
<name><surname>Silva</surname><given-names>PRS</given-names></name>
<name><surname>Lima</surname><given-names>IR</given-names></name>
<name><surname>Tada</surname><given-names>MT</given-names></name>
<name><surname>Oliveira</surname><given-names>TGM</given-names></name>
<etal/>
</person-group><article-title>Screening for Familial Hypercholesterolemia in Small Towns: Experience from 11 Brazilian Towns in the Hipercolbrasil Program</article-title><source>
Arq Bras Cardiol
</source><year>2022</year><volume>118</volume><issue>4</issue><fpage>669</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.36660/abc.20201371</pub-id><pub-id pub-id-type="pmid">35137788</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Izar</surname><given-names>MCO</given-names></name>
<name><surname>Giraldez</surname><given-names>VZR</given-names></name>
<name><surname>Bertolami</surname><given-names>A</given-names></name>
<name><surname>Santos</surname><given-names>RDD</given-names><suffix>Filho</suffix></name>
<name><surname>Lottenberg</surname><given-names>AM</given-names></name>
<name><surname>Assad</surname><given-names>MHV</given-names></name>
<etal/>
</person-group><article-title>Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021</article-title><source>
Arq Bras Cardiol
</source><year>2021</year><volume>117</volume><issue>4</issue><fpage>782</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.36660/abc.20210788</pub-id><pub-id pub-id-type="pmid">34709306</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faria</surname><given-names>JR</given-names><suffix>Neto</suffix></name>
<name><surname>Bento</surname><given-names>VF</given-names></name>
<name><surname>Baena</surname><given-names>CP</given-names></name>
<name><surname>Olandoski</surname><given-names>M</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>LG</given-names></name>
<name><surname>Abreu</surname><given-names>GA</given-names></name>
<etal/>
</person-group><article-title>ERICA: Prevalence of Dyslipidemia in Brazilian Adolescents</article-title><source>
Rev Saude Publica
</source><year>2016</year><volume>50</volume><issue>Suppl 1</issue><fpage>10</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1590/S01518-8787.2016050006723</pub-id><pub-id pub-id-type="pmid">27143610</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>RD</given-names></name>
<name><surname>Pereira</surname><given-names>C</given-names></name>
<name><surname>Cesena</surname><given-names>F</given-names></name>
<name><surname>Laurinavicius</surname><given-names>AG</given-names></name>
<name><surname>Tabone</surname><given-names>V</given-names></name>
<name><surname>Bittencourt</surname><given-names>MS</given-names></name>
</person-group><article-title>Cardiovascular Risk Misperception and Low Awareness of Familial Hypercholesterolemia in Individuals with Severe Hypercholesterolemia</article-title><source>
Arq Bras Cardiol
</source><year>2021</year><volume>116</volume><issue>4</issue><fpage>706</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.36660/abc.20190516</pub-id><pub-id pub-id-type="pmid">33566934</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>RD</given-names></name>
<name><surname>Kashiwagi</surname><given-names>NM</given-names></name>
<name><surname>Cesena</surname><given-names>FY</given-names></name>
<name><surname>Assis</surname><given-names>SRL</given-names></name>
<name><surname>Nieri</surname><given-names>J</given-names></name>
<name><surname>Minanni</surname><given-names>CA</given-names></name>
<etal/>
</person-group><article-title>Uncontrolled Cholesterol in Individuals with Severe Hypercholesterolemia in a Health Evaluation Program in Brazil</article-title><source>
Arq Bras Cardiol
</source><year>2024</year><volume>121</volume><issue>11</issue><elocation-id>e20240116</elocation-id><pub-id pub-id-type="doi">10.36660/abc.20240116</pub-id><pub-id pub-id-type="pmid">39607222</pub-id>
</element-citation></ref></ref-list></back><sub-article article-type="translation" id="S1" xml:lang="en"><front-stub><article-id pub-id-type="doi">10.36660/abc.20250178i</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Editorial</subject></subj-group></article-categories><title-group><article-title>Detecting Familial Hypercholesterolemia in Adolescents: Universal Screening is Key</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1051-9434</contrib-id><name><surname>Yue Cesena</surname><given-names>Fernando</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c2" ref-type="corresp"/></contrib><aff id="aff2">
<label>1</label>
<addr-line>
<named-content content-type="city">S&#x000e3;o Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Instituto Dante Pazzanese de Cardiologia, S&#x000e3;o Paulo, SP - Brazil</institution>
</aff></contrib-group><author-notes><corresp id="c2">
<label>Mailing Address:</label>
<bold>Fernando Yue Cesena</bold>
&#x02022; Instituto Dante Pazzanese de Cardiologia - Se&#x000e7;&#x000e3;o de Hipertens&#x000e3;o e Tabagismo - Av. Dr. Dante Pazzanese, 500. Postal Code
<postal-code>04012-909</postal-code>
, S&#x000e3;o Paulo, SP - Brazil E-mail:
<email>cesenaf@gmail.com</email>
</corresp></author-notes><kwd-group><title>Keywords</title><kwd>Hypercholesterolemia</kwd><kwd>Adolescent</kwd><kwd>Mass Screening</kwd></kwd-group></front-stub><body><p>Familial hypercholesterolemia (FH) is a genetic disorder characterized by impaired clearance of low-density lipoprotein (LDL) particles from plasma to hepatocytes, resulting in elevated plasma LDL-Cholesterol (LDL-C) levels and a significantly increased risk of premature atherosclerotic cardiovascular disease (ASCVD). Recent meta-analyses indicate an FH prevalence of approximately 1 in 310 individuals in the general population.<sup>
<xref rid="B1" ref-type="bibr">1</xref>
,
<xref rid="B2" ref-type="bibr">2</xref>
</sup>Importantly, FH remains substantially underdiagnosed, and most affected individuals live with LDL-C levels above recommended targets.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup></p><p>Early identification of FH is critical for preventing ASCVD events. From a pathophysiological perspective, atherosclerosis develops due to cumulative arterial exposure to elevated LDL particles. Both the magnitude of excessive LDL particles in plasma and the duration of exposure are relevant for plaque development and progression.<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>In this regard, FH is of particular concern because affected individuals have very high LDL-C levels since birth/childhood. Early diagnosis and consequent awareness of the problem increase the chance of adopting a healthy lifestyle in the long term. Early LDL-C lowering improves endothelial function, attenuates atherosclerosis progression, and diminishes the risk of coronary events.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
,
<xref rid="B5" ref-type="bibr">5</xref>
,
<xref rid="B6" ref-type="bibr">6</xref>
</sup></p><p>In this issue of
<italic toggle="yes">Arquivos Brasileiros de Cardiologia</italic>
, a substudy from ERICA, a cross-sectional Brazilian study conducted in 2013&#x02013;2014, evaluates lipid abnormalities suggestive of FH in adolescents aged 12&#x02013;17 from the Curitiba metropolitan region. Among 2,383 adolescents assessed, 11 (approximately 0.5% or 1 in 217) exhibited LDL-C &#x0003e;160 mg/dL or non-HDL cholesterol &#x0003e;190 mg/dL. Cascade screening was applied to first-degree relatives. None of the 7 students evaluated had a diagnosis of possible or probable FH according to the modified version of the Dutch Lipid Clinic Network (Dutch MEDPED), while 3 among 15 first-degree relatives (20%) had criteria for possible or probable FH.<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>The study has limitations, including the lack of a definitive diagnosis of FH by genetic test. Still, it offers an opportunity to discuss relevant aspects of FH diagnosis in the youth.</p><p>The absence of adolescents with positive criteria for FH using the Dutch MEDPED agrees with the recommendation against the use of this score for diagnosing FH in children and adolescents.<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>These individuals less frequently have typical FH features such as tendon xanthoma compared to adults.<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup>Furthermore, clinical ASCVD, a criterion in the Dutch MEDPED, typically occurs in adult life in individuals with heterozygous FH. Therefore, FH should be suspected in children/adolescents when the LDL-C is markedly elevated (&#x0003e;190 mg/dL untreated) or in those with moderately elevated LDL-C alongside parental history of premature coronary heart disease, severely elevated LDL-C, or an identified genetic mutation causing FH.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
,
<xref rid="B5" ref-type="bibr">5</xref>
</sup></p><p>Genetic testing for FH-causing variants should be made whenever feasible.<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>Identifying a pathogenic variant indicates a higher cardiovascular risk, improves treatment adherence, and may prompt cascade screening to identify affected relatives.<sup>
<xref rid="B9" ref-type="bibr">9</xref>
,
<xref rid="B10" ref-type="bibr">10</xref>
</sup>In Brazil, the Hipercol Brasil (
<ext-link xlink:href="https://hipercolbrasil.com.br/o-programa/" ext-link-type="uri">https://hipercolbrasil.com.br/o-programa/</ext-link>
), an FH cascade genetic screening program, exemplifies a successful initiative to facilitate FH genetic diagnosis even in regions distant from specialized centers.<sup>
<xref rid="B10" ref-type="bibr">10</xref>
,
<xref rid="B11" ref-type="bibr">11</xref>
</sup></p><p>At the community level, early diagnosis of FH depends on an effective screening strategy, which constitutes a strong argument in favor of universal screening. Accordingly, the 2021 Update of the Brazilian Guideline for FH recommends lipid profiling for all children starting at age 10 or as early as age 2 in specific situations (e.g., parental history of premature coronary heart disease or very high LDL-C).<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>The chance of detecting hypercholesterolemia in adolescents is not negligible. A previous report from the ERICA study showed that 25% of female and 15% of male adolescents had high levels of plasma total cholesterol (&#x02265;170 mg/dL), while an additional 26% of females and 23% of males had total cholesterol between 150 mg/dL and 169 mg/dL, resulting in an estimate of almost 3 million Brazilian adolescents with elevated blood cholesterol.<sup>
<xref rid="B13" ref-type="bibr">13</xref>
</sup></p><p>The lack of a structured strategy for universal lipid screening in routine practice represents a missed opportunity for early cardiovascular risk reduction through lifestyle interventions and preventive therapies. Other significant barriers remain, including low awareness of FH, especially in children/adolescents, patient misperceptions regarding cardiovascular risk, and low LDL-C target achievement in individuals with severe hypercholesterolemia.<sup>
<xref rid="B14" ref-type="bibr">14</xref>
,
<xref rid="B15" ref-type="bibr">15</xref>
</sup>Addressing these issues requires a multifaceted approach involving governmental health agencies, medical societies, and organized groups of patients, with comprehensive programs and educational campaigns targeting healthcare professionals and the broader community. These actions are essential to reduce FH burden effectively and associated ASCVD risks.</p></body><back><fn-group><fn fn-type="other" id="fn2"><p><bold>Short Editorial related to the article:</bold> Cascade Screening in Adolescents with Lipid Disorders Suggestive of Familial Hypercholesterolemia: Findings from the ERICA Study in Curitiba</p></fn></fn-group></back></sub-article></article>